ClinicalTrials.gg

Program

GSK4382276A

A development code. Also written as “Flu mRNA (Formulation B1)”, “Flu mRNA (Formulation B3)” and “Flu mRNA(Formulation A)”.

In GlaxoSmithKline's pipeline, mRNA vaccine. Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.

Furthest: phase 2, since Aug 6, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline30 open or runningphase 2since Aug 6, 2025Jun 28, 2022none ahead
  • Named in GlaxoSmithKline’s own pipeline as mRNA Seasonal Flu GSK4382276, phase 3, as of Sep 30, 2026 (source).

Also a collaborator on its studies: BioNTech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 28, 2022First study: phase 1 study in Influenza, HumanFirst studyNCT05446740 · 324 enrolled · Belgium, Canada, Spain
  2. Aug 6, 2025Phase 2 study in Influenza, HumanNCT07121192 · 776 enrolled · United States
  3. Oct 1, 2025Phase 2 study in Influenza, HumanNCT07204964 · 971 enrolled · United States, Belgium

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“mRNA vaccine”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07204964Influenza, Human · United States, Belgium2CompletedAug 24, 2026971
NCT07121192Influenza, Human · United States2CompletedMay 11, 2026776
NCT05446740Influenza, Human · Belgium, Canada, Spain1CompletedMar 26, 2024324

How it is read

Names in the registry

  • “Flu mRNA (Formulation B1)”, 1 entry
  • “Flu mRNA (Formulation B3)”, 1 entry
  • “Flu mRNA(Formulation A)”, 1 entry
  • “Flu mRNA (Formulation A)”, 1 entry
  • “Flu mRNA (Formulation B)”, 1 entry

Codes read as this program: GSK4382276A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.